Cargando…
Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
OBJECTIVE: Recombinant human growth hormone (rhGH) replacement therapy in children generally requires daily subcutaneous (sc) injections, which may be inconvenient for patients. Jintrolong(®) is a PEGylated rhGH with the purpose of weekly sc injections. The aim of the current study was to examine th...
Autores principales: | Hou, Ling, Chen, Zhi-hang, Liu, Dong, Cheng, Yuan-guo, Luo, Xiao-ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690642/ https://www.ncbi.nlm.nih.gov/pubmed/26719670 http://dx.doi.org/10.2147/DDDT.S93183 |
Ejemplares similares
-
The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
por: Liang, Yan, et al.
Publicado: (2022) -
The effects of recombinant human growth hormone therapy on thyroid function in pediatric patients with growth hormone deficiency
por: Yao, Qian, et al.
Publicado: (2021) -
PEGylated Recombinant Human Growth Hormone Jintrolong(®) Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients
por: Wu, Wei, et al.
Publicado: (2022) -
Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies
por: Luo, Xiaoping, et al.
Publicado: (2017) -
Use of PEGylated Recombinant Human Growth Hormone in Chinese Children with Growth Hormone Deficiency: A 24-Month Follow-Up Study
por: Qiao, Yu, et al.
Publicado: (2019)